Lilly Schwieler1, Markus K Larsson1, Elisabeth Skogh2, Magdalena E Kegel1, Funda Orhan1, Sally Abdelmoaty1, Anja Finn1, Maria Bhat3, Martin Samuelsson2, Kristina Lundberg2, Marja-Liisa Dahl4, Carl Sellgren5, Ina Schuppe-Koistinen3, Camilla Svensson1, Sophie Erhardt1, Göran Engberg1. 1. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. 2. Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden. 3. AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 4. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Accumulating evidence indicates that schizophrenia is associated with brain immune activation. While a number of reports suggest increased cytokine levels in patients with schizophrenia, many of these studies have been limited by their focus on peripheral cytokines or confounded by various antipsychotic treatments. Here, well-characterized patients with schizophrenia, all receiving olanzapine treatment, and healthy volunteers were analyzed with regard to cerebrospinal fluid (CSF) levels of cytokines. We correlated the CSF cytokine levels to previously analyzed metabolites of the kynurenine (KYN) pathway. METHODS: We analyzed the CSF from patients and controls using electrochemiluminescence detection with regard to cytokines. Cell culture media from human cortical astrocytes were analyzed for KYN and kynurenic acid (KYNA) using high-pressure liquid chromatography or liquid chromatography/mass spectrometry. RESULTS: We included 23 patients and 37 controls in our study. Patients with schizophrenia had increased CSF levels of interleukin (IL)-6 compared with healthy volunteers. In patients, we also observed a positive correlation between IL-6 and the tryptophan:KYNA ratio, indicating that IL-6 activates the KYN pathway. In line with this, application of IL-6 to cultured human astrocytes increased cell medium concentration of KYNA. LIMITATIONS: The CSF samples had been frozen and thawed twice before analysis of cytokines. Median age differed between patients and controls. When appropriate, all present analyses were adjusted for age. CONCLUSION: We have shown that IL-6, KYN and KYNA are elevated in patients with chronic schizophrenia, strengthening the idea of brain immune activation in patients with this disease. Our concurrent cell culture and clinical findings suggest that IL-6 induces the KYN pathway, leading to increased production of the N-methyl-D-aspartate receptor antagonist KYNA in patients with schizophrenia.
BACKGROUND: Accumulating evidence indicates that schizophrenia is associated with brain immune activation. While a number of reports suggest increased cytokine levels in patients with schizophrenia, many of these studies have been limited by their focus on peripheral cytokines or confounded by various antipsychotic treatments. Here, well-characterized patients with schizophrenia, all receiving olanzapine treatment, and healthy volunteers were analyzed with regard to cerebrospinal fluid (CSF) levels of cytokines. We correlated the CSF cytokine levels to previously analyzed metabolites of the kynurenine (KYN) pathway. METHODS: We analyzed the CSF from patients and controls using electrochemiluminescence detection with regard to cytokines. Cell culture media from human cortical astrocytes were analyzed for KYN and kynurenic acid (KYNA) using high-pressure liquid chromatography or liquid chromatography/mass spectrometry. RESULTS: We included 23 patients and 37 controls in our study. Patients with schizophrenia had increased CSF levels of interleukin (IL)-6 compared with healthy volunteers. In patients, we also observed a positive correlation between IL-6 and the tryptophan:KYNA ratio, indicating that IL-6 activates the KYN pathway. In line with this, application of IL-6 to cultured human astrocytes increased cell medium concentration of KYNA. LIMITATIONS: The CSF samples had been frozen and thawed twice before analysis of cytokines. Median age differed between patients and controls. When appropriate, all present analyses were adjusted for age. CONCLUSION: We have shown that IL-6, KYN and KYNA are elevated in patients with chronic schizophrenia, strengthening the idea of brain immune activation in patients with this disease. Our concurrent cell culture and clinical findings suggest that IL-6 induces the KYN pathway, leading to increased production of the N-methyl-D-aspartate receptor antagonist KYNA in patients with schizophrenia.
Authors: Linnéa Asp; Maria Holtze; Susan B Powell; Håkan Karlsson; Sophie Erhardt Journal: Int J Neuropsychopharmacol Date: 2009-07-17 Impact factor: 5.176
Authors: Janine Doorduin; Erik F J de Vries; Antoon T M Willemsen; Jan Cees de Groot; Rudi A Dierckx; Hans C Klein Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Mary-Frances O'Connor; Julie E Bower; Hyong Jin Cho; J David Creswell; Stoyan Dimitrov; Mary E Hamby; Michael A Hoyt; Jennifer L Martin; Theodore F Robles; Erica K Sloan; Kamala S Thomas; Michael R Irwin Journal: Brain Behav Immun Date: 2009-04-21 Impact factor: 7.217
Authors: Stefan Busse; Mandy Busse; Kolja Schiltz; Hendrik Bielau; Tomasz Gos; Ralf Brisch; Christian Mawrin; Andrea Schmitt; Wolfgang Jordan; Ulf J Müller; Hans-Gert Bernstein; Bernhard Bogerts; Johann Steiner Journal: Brain Behav Immun Date: 2012-08-14 Impact factor: 7.217
Authors: Daniel Lindqvist; Shorena Janelidze; Peter Hagell; Sophie Erhardt; Martin Samuelsson; Lennart Minthon; Oskar Hansson; Maria Björkqvist; Lil Träskman-Bendz; Lena Brundin Journal: Biol Psychiatry Date: 2009-03-06 Impact factor: 13.382
Authors: Linda L Carpenter; George R Heninger; Robert T Malison; Audrey R Tyrka; Lawrence H Price Journal: J Affect Disord Date: 2004-04 Impact factor: 4.839
Authors: K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka Journal: Mol Psychiatry Date: 2017-02-14 Impact factor: 15.992
Authors: M K Larsson; A Faka; M Bhat; S Imbeault; M Goiny; F Orhan; A Oliveros; S Ståhl; X C Liu; D S Choi; K Sandberg; G Engberg; L Schwieler; S Erhardt Journal: Neurochem Res Date: 2016-05-10 Impact factor: 3.996
Authors: Juan A Gallego; Emily A Blanco; Sehba Husain-Krautter; E Madeline Fagen; Paula Moreno-Merino; Juan A Del Ojo-Jiménez; Anthony Ahmed; Thomas L Rothstein; Todd Lencz; Anil K Malhotra Journal: Schizophr Res Date: 2018-07-17 Impact factor: 4.939
Authors: Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2017-07-01 Impact factor: 9.306
Authors: Jonathan L Hess; Daniel S Tylee; Rahul Barve; Simone de Jong; Roel A Ophoff; Nishantha Kumarasinghe; Paul Tooney; Ulrich Schall; Erin Gardiner; Natalie Jane Beveridge; Rodney J Scott; Surangi Yasawardene; Antionette Perera; Jayan Mendis; Vaughan Carr; Brian Kelly; Murray Cairns; Ming T Tsuang; Stephen J Glatt Journal: Schizophr Res Date: 2016-07-20 Impact factor: 4.939